Board of Directors

ID-10091071

 

William Gerber, MBA

Bill Gerber
Executive Vice President and Chief Financial Officer
TD Ameritrade Holding Corporation
(NYSE: AMTD)

Bill Gerber was Executive Vice President and Chief Financial Officer of TD Ameritrade Holding Corporation. While with TD Ameritrade, Gerber oversaw investor relations, business development, certain treasury functions and finance operations, including accounting, business planning and forecasting, external and internal reporting, tax and competitive intelligence. He also serves as a member of the Company’s senior operating committee, that shaped the strategic focus of the organization.

Gerber was with TD Ameritrade from 1999 to 2015. He served as managing director of finance, during which time he played a major role in evaluating merger and acquisition opportunities for the Company, including the National Discount Brokers (2001), Datek Online Holdings (2002), and TD Waterhouse (2005) transactions. He served in this capacity until his appointment as chief financial officer in October 2006, where he also played a role in evaluating the thinkorswim (2009) acquisition for the Company.

Prior to joining the Company, Gerber spent eight years with Coopers & Lybrand, now known as PriceWaterhouseCoopers, serving as an audit manager primarily focused on public company clients. He was named a member of the CNBC CFO Council in 2013 and 2014. Gerber was also named to Institutional Investor Magazine’s “All America Executive Team” as one of the top 3 CFOs in the “Brokers, Asset Managers and Exchanges” category in 2012, 2013 and 2014. Gerber holds a bachelor’s degree in accounting from the University of Michigan.

About TD Ameritrade Holding Corporation

Millions of investors and independent registered investment advisors (RIAs) have turned to TD Ameritrade’s (NYSE: AMTD) technology, people and education to help make investing and trading easier to understand and do. Online or over the phone. In a branch or with an independent RIA. First-timer or sophisticated trader. Our clients want to take control, and we help them decide how – bringing Wall Street to Main Street for more than 39 years. An official sponsor of the 2014 and 2016 U.S. Olympic and Paralympic Teams, TD Ameritrade has time and again been recognized as a leader in investment services. Please visit the TD Ameritrade’s newsroom or www.amtd.com for more information.

Brokerage services provided by TD Ameritrade, Inc., member FINRA (www.FINRA.org) /SIPC (www.SIPC.org) /NFA (www.nfa.futures.org)

 

C. Steven Powell, MD
C. Steven Powell MD is Professor of Surgery and chief of the section of vascular surgery at the East Carolina Heart Institute, Department of Cardiovascular Sciences of the Brody School of Medicine at East Carolina University. He was assistant professor of surgery at the state university of New York at Buffalo for two years before joining the faculty at the school of medicine at East Carolina University twenty seven years ago.Dr. Powell has a long history as a private investor and is a student of business and markets. During the last round of private equity funding for CTMG, Dr. Powell served as advisor to the Company in helping with closing the series C preferred offering. Dr. Powell has an extensive list of academic publications and awards including best teacher and best doctors in North Carolina. Among his numerous committee assignments and leadership positions he was a member of the clinical trials advisory committee for the Department of Cardiovascular Sciences. He has participated as a principal investigator in numerous clinical trials and has combined this medical perspective with his business expertise to forecast clinical trial industry trends and targets.

Dr. Powell received his undergraduate degree from the University of Kentucky and is a cum laude graduate of the UK medical school. His surgical training was performed at Vanderbilt University and he was a fellow in vascular surgery at the Ochsner Clinic in New Orleans, La.

 

Michael Smith
Mike Smith has over 35 years of experience in the asset management and institutional sales and trading business. His varied background includes experience in both the money management and brokerage businesses.

Mr. Smith’s accomplishments are highlighted by a 16-year career with Merrill Lynch & Co., where he was a Managing Director serving in various institutional sales management roles. In addition to managing all U.S. institutional regional offices, he created a successful strategy for interfacing with the top 100 investor clients in the world.
Mr. Smith began his career in 1966 as a securities analyst at the Mercantile Bank in Dallas where he was a security analyst. After authoring the Weekly Bond Letter for Burnham & Company, he became a founding partner of Earp, Kenney and Smith, a regional brokerage company in Dallas. As Director of Research there, he was involved in chartering a small business investment corporation (SBIC) engaged in start-up venture capital investments and helped start a mutual fund. In 1971, Mr. Smith joined Dean Witter & Co., opening their first office in Texas.

After joining The Boston Company as a Portfolio Manager in 1975, Mr. Smith held the title of President and Chief Investment Officer of the company’s west coast investment management subsidiary located in Los Angeles. He also served on the Investment Policy Committee of the parent company. In 1980, Mr. Smith returned to the brokerage business as head of the equity institutional sales group for First Boston in Dallas.

Currently, Mr. Smith is a private investor in Glen Ellyn, IL. He serves as a member of the Board of Trustees of the Ivy Funds, a mutual fund family managed by Waddell & Reed, the Northwestern Mutual Series Funds, and the TDAX funds. He is currently a member of the Executive Board of the Cox Business at Southern Methodist University
Mr. Smith holds a BBA and MBA from Southern Methodist University and has achieved the Chartered Financial Analyst designation.

 

Ferdinand Massari, MD
Dr. Ferdinand (Ferd) Massari serves as Chief Medical Officer at BBB Therapeutics, a biotech company based in the Netherlands that focuses on treatment of serious brain diseases. He has over 25 years’ experience in the Pharmaceutical industry having led teams in clinical research, regulatory affairs, medical affairs and pharmacovigilance. Prior to BBB Therapeutics, Ferd held executive positions at Shire, Pfizer and Pharmacia as well as at numerous small biotech companies. He has been responsible for multiple product registrations and has overseen programs from preclinical development through registration in multiple therapeutic areas such as infectious diseases, urology, oncology and genetic diseases. He began his pharmaceutical career leading the HIV clinical research effort at Merck Research Laboratories.

Dr. Massari trained in adult Allergy and Immunology, with a research focus on the cellular immunology of HIV infection, in the laboratory of Dr. Anthony S Fauci, Director of the National Institute of Allergy and Infectious Diseases. He is a graduate of Jefferson Medical College of Philadelphia and holds a B.A. in Political Science from the University of Maryland, Baltimore County.

 

R. Dennis Steed, MD
R. Dennis Steed, MD is an Associate Professor of Pediatrics and a long-standing member of the section of pediatric cardiology at the East Carolina Heart Institute of the Brody School Medicine at East Carolina University. He has served on the CTMG Board of Directors since its inception in April, 2004, and played critical roles in explaining the value position to physicians and their institutions interested in partnering with CTMG to conduct clinical trials, and others interested in considering CTMG as an investment opportunity. Dr. Steed has also provided the company with insight into cardiac medical subtleties that are often encountered in conducting any clinical trial. Dr. Steed has been an active and successful investor in equity markets for over 25 years. In the process he has developed a considerable fund of knowledge in business and in the markets. Dr Steed has a number of academic publications and has received a number of awards including best teacher and best doctors in North Carolina. He established the fetal echocardiography program at the school of medicine which is one of the most active in the southeastern United States.

Dr. Steed has been active in the community, participating on a number of boards of directors, including Michael Jordan Celebrity Golf Classic and The Ronald McDonald House of Eastern North Carolina, where he has twice served as board president.

Dr. Steed received his undergraduate degree from the University of Georgia and his medical degree from the Medical College of Georgia in Augusta. He underwent his pediatric training at the Arizona Health Sciences Center in Tucson Arizona, and completed his fellowship in pediatric cardiology at the Children’s Hospital of Cincinnati.

 

Anton-Lewis Usala, MD, Chairman
Dr. Usala founded CTMG, Inc. in 2004 to address the gaps he observed in site clinical trial quality systems first as a University Medical Center researcher, and later as he directed the Biotechnology company he founded (Encelle, Inc.) into FDA monitored clinical trials. While at his biotechnology company, Dr. Usala observed all facets of investigational product development are controlled by cGXP-linked quality systems, except for the human clinical research portion conducted at Physician Investigator sites. Dr. Usala devised Quality Systems, using the principles of cGMP review and Corrective and Preventative Action (CAPA) Systems, for use at clinical investigative sites with the goal of effectively and reproducibly assuring site performance. Since April 2004, Dr. Usala has led the only clinical trial management group to effectively implement, design and utilize design-reviewed GMP-like processes, under layered Quality Systems at the point of clinical trial service delivery, to ensure that what is intended in the investigative protocol is actually done at the investigative site. His designed systems approach has resulted in CTMG’s rapid patient enrollment and retention, resulting in most sites reaching or exceeding contracted patient numbers (compared to only 25% site success nationally). Dr. Usala is an author of 18 U.S. patents, and has testified seven times before different U.S. Senate and House subcommittees on issues related to regenerative medicine research. Dr. Usala received his undergraduate degree in Biology and Political Science from Swarthmore College, his Medical Degree from Jefferson Medical College, and his pediatric and pediatric endocrinology/pharmacology training at Case Western Reserve University.